Novo Nordisk at BioTechX Europe 2026
Oct 6–8, 2026 Basel, Switzerland ~3k attendees Website
Novo Nordisk takes part in 14 sessions at BioTechX Europe 2026 in Basel, and exhibits. Its program centres on AI agents in clinical development, software that helps teams make trial and operational decisions, and on the data practices behind them. It also weighs whether to build, buy or partner for such tools, and why digital transformation projects stall when staff do not adopt them.
| Organization | BioTechX Europe 2026 Attendance |
|---|---|
Novo Nordisk Bagsværd, Denmark | |
Danish pharmaceutical company making medicines for diabetes, obesity and rare blood and endocrine diseases. | Booth Exhibiting (no floor booth listed) Keynote Tue Oct 6 09:40 The use of agentic AI in R&D AI & large language models Talk Tue Oct 6 11:45 Talk Tue Oct 6 16:10 Panel Tue Oct 6 17:25 Build, Buy, or Partner: From Agentic AI Hype to Enterprise Value How drug companies should choose between building, buying or partnering for AI that acts on its own, and how to oversee it. Panel Tue Oct 6 17:25 Panel Tue Oct 6 17:25 Gaining a competitive advantage in drug discovery through linked, multi-dimensional data at scale What it takes to build large, well-labeled genome and cell datasets for AI drug discovery, and to link different datasets together. Chair Wed Oct 7 11:40 Talk Wed Oct 7 13:05 Talk Wed Oct 7 16:30 Panel Wed Oct 7 17:25 Panel Wed Oct 7 17:25 Panel Wed Oct 7 17:25 Talk Thu Oct 8 12:10 |
Instantly find 20 buyers from Novo Nordisk
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by Terrapinn or BioTechX. Submit a correction